This symposium will bring together a large international network of partners from academia and industry, to explore the use of novel reagents and launch ambitious compound development and translational projects. Its programme will cover recent advances, showcase novel potential targets for research, and establish new collaborations. An all day event, taking place on 14 June 2018 at St Catherine's College, Oxford. Register here.
A 3-day interactive course with lectures, group work, hands-on tutorials and supervised statistical sessions for clinicians, researchers and policy makers taking place 2-4 July 2018 at the University of Oxford.
Dr Bob Taylor works on drug trials for vivax and falciparum malaria. In contrast with falciparum malaria, vivax malaria can relapse from dormant stage parasites in the patient’s liver. Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.
The rapid elimination of potentially untreatable P. falciparum malaria in South-East Asia is possible, according to a ground-breaking new study published today in The Lancet. The study authors say that setting up community-based malaria clinics for early diagnosis, treatment and monitoring, combined with mass antimalarial drug administration (MDA) to everyone living in ‘hotspot’ areas.
Pailin, a small settlement nestling in tropical rainforest near Cambodia’s border with Thailand, lies at the heart of a region that has seen successive waves of resistance to malaria drugs arise in local people and then spread across the globe. As new waves of the disease threaten our health, worried scientists want to conduct a mass inoculation in a Cambodian region where new vaccines always seem to stop being effective
Researchers in Ireland, the UK, including Roman Fischer and Benedikt Kessler from the Target Discovery Institute and US have discovered a new metabolic process in the body that can switch off inflammation. “itaconate” – a molecule derived from glucose – “acts as a powerful off switch for macrophages”, thereby reducing inflammation. The discovery published in Nature offers more effective treatment of inflammatory diseases such as arthritis, inflammatory bowel disease and heart disease.
Thurs 26 April 2018, 1 - 2 pm
Lecture Theatre 1
Clinical Immunology: "Chasing waterfalls: when the complement cascade spills over"
Dr Adrian Shields
Dermatology: "Naughty Neutrophils"
Dr Crystal Williams and Dr Sanju Arianayagam
Chair: Prof Chris Conlon
View upcoming medical grand rounds